key: cord-0703733-bd0nk0n8 authors: Patra, Pratap Kumar; Das, Rashmi Ranjan; Banday, Aaqib Zaffar; Singh, Mini; Goyal, Kapil; Jindal, Ankur Kumar; Singh, Surjit title: Non-SARS, non-MERS human coronavirus infections and risk of Kawasaki disease: a meta-analysis date: 2021-11-26 journal: Future virology DOI: 10.2217/fvl-2021-0176 sha: d0a65e22f49301ccef269a43c27a25181482223f doc_id: 703733 cord_uid: bd0nk0n8 Aim: To study the association between non-SARS, non-MERS human coronavirus (HCoV) infections and Kawasaki disease (KD). Methods: Meta-analysis of observational studies published until 1 May 2021. Results: Out of 571 papers retrieved through database search, 10 provided data of 17,732 children. Age ranged from 2 months–14.9 years with 66% being male and 71% being complete KD. Compared with controls, there was an increased risk of developing KD in those detected to have HCoV infection (OR: 2.3 [95% CI: 1.06–4.99]; p = 0.03). The GRADE evidence for all outcomes was of ‘low-certainty’. Conclusion: A ‘low certainty’ of evidence suggests an increased risk of KD in children infected with HCoV. We need multi-center, prospective studies to support or refute this finding. PROSPERO protocol registration: CRD42021251582. infection (non-SARS and non-MERS) and KD. We tried to find out if HCoV infection was increasing the risk of development of KD in children of all age groups. Types of studies Observational studies that aimed at studying the association of HCoV infection with KD in both community and hospital settings were included. Children of all age groups/sexes were included. Types of exposure Participants in exposure group included those with HCoV infection (confirmed by either RT-PCR or serology) and KD. In control group, children had HCoV infection but no features of KD. • Risk of development of KD in those infected with HCoVs. • Risk of development of KD in those infected with different serotypes of HCoVs (e.g., HKU1, HCoV OC43, HCoV 229E and HCoV NL63). The following databases were searched systematically from the year 1967 to 1 May 2021: PubMed/MEDLINE, Google Scholar, Embase and pre-print servers (medRxiv, bioRxiv, OSF preprints, Pre-prints.org). The PubMed/MEDLINE search strategy used the various MeSH and free text terms for 'coronavirus', 'coronavirinae', 'novel coronavirus', HCoV, SARS CoV-2, COVID-19, MERS-CoV, 'Kawasaki disease', 'Kawasaki syndrome', 'mucocutaneous lymph node syndrome', 'observational studies', 'children', 'pediatric', using the Boolean operators. No language restrictions were applied. The search results were reviewed to identify relevant studies. The data were extracted by using a pre-designed data extraction form and tested a priori. We independently extracted the following information from each study: author, year, location (country), study design, setting (hospital or community), method of recruitment, inclusion criteria, risk of bias, participants (age, sex, sample size and diagnosis), exposure (type of viruses, methods employed for diagnosis and method of ascertainment), outcomes (outcome definition, valid unit of measurement, time points of collection and reporting), lost to follow up and miscellaneous data (key conclusions, references to other studies and additional data required). We independently assessed quality by using the Newcastle-Ottawa scale (NOS) for observational studies [10] . It assesses the quality of studies under three major domains: selection of studies, comparability and outcome/exposure. Any disagreements were resolved by discussion. Dealing with missing data The missing data were described that included dropouts in selected studies. Difference in dropout rates may lead to biased estimates of the effect size. Furthermore, bias may arise if the reasons for dropouts vary across different groups in different studies. Data were analyzed using Review Manager (RevMan, v.5.3, The Cochrane Collaboration, Copenhagen, Denmark) [11] . Data from included studies were pooled and expressed as odds ratio (OR) with 95% CI. A p-value < 0.05 was considered statistically significant. Inter-study heterogeneity was assessed by Cochrane's Q (χ 2 p < 0.10) and quantified by I 2 . An I 2 ≥50% indicated 'substantial' heterogeneity and ≥75% indicated 'considerable' heterogeneity [12] . Causes of substantial or considerable heterogeneity were explored and, sensitivity and/or sub-group analyses were carried out where feasible. We used both random-and fixed-effect models to see any difference in pooled effect. We constructed the funnel plot from primary outcome to ascertain any publication bias [13] . We used GRADE Profiler software (v.3.2) to assess certainty of evidence [14] . The software uses five parameters for rating the certainty of evidence. The parameters used are risk of bias, inconsistency of results or unexplained heterogeneity, indirectness of evidence, imprecision of results and publication bias. Of 571 total citations retrieved, full text of 11 papers was assessed for eligibility, and one duplicate paper was excluded ( Figure 1 ) [15] . Of the remaining 10 eligible studies (17,732 children), we were able to do a meta-analysis of seven studies including 17,615 children (cases: 555; controls: 17,060) ( Table 1 ). Age range of included children was 0.2-14.9 years, 66% were male and 71% had classic KD. Eight studies were case-control studies [16] [17] [18] [19] [20] [21] [22] [23] and two were prospective studies [24, 25] . The studies had been conducted in the following countries: USA (n = 5), Japan (n = 2), Taiwan (n = 2), The Netherlands (n = 1) and Germany (n = 1). Two studies employed serology (antibody assay) and immunofluorescence for diagnosis of HCoV infection, whereas the rest employed viral detection (RT- PCR and/or culture) method [20, 21] . Respiratory samples (from nose, nasopharynx or throat) were used by studies that used viral detection methods. Different studies have assessed the association of different serotypes of HCoVs with KD, and details are depicted in Table 1 . None of the studies was having a risk of bias in selection of cases, but four were at a high risk of bias for selection of controls [17, 18, 20, 21] . Two studies were at high risk of bias for comparability of cases and controls [18, 21] . All studies were having a low risk of bias for exposure parameters ( Table 2) . Overall analysis: Seven studies were able to contribute data to the pooled analysis. Both fixed-and random-effect models were employed to see whether the findings were significant or not, as significant heterogeneity was noted among included studies (I 2 = 58%; p = 0.03). There was an increased risk (odds) of developing KD in those detected to have infection with HCoV as found in both the models (random-effect model Subgroup analysis: we separately analyzed studies employing different diagnostic methods for HCoV (RT-PCR/viral detection or antibody assay). Overall analysis was not significant for studies employing either RT-PCR/viral detection (OR: 3.22 [95% CI: 0.79 to 13.08]; p = 0.1) or antibody assay (OR: 1.75 [95% CI: 0.96 to 3.18]; p = 0.07). As there was significant heterogeneity among studies, we did sensitivity analysis by removing one study [16] . Pooled data was significant without any remarkable heterogeneity ( We separately analyzed data from included studies that reported different serotypes of HCoV (NL63, OC43, 229E). However, none of the serotypes was individually associated with risk of development of KD. Funnel plot was asymmetrical showing publication bias ( Figure 3 ). Evidence generated was of 'low certainty' for all outcomes (primary and secondary). Likely reasons were heterogeneity among studies, poor methodological design and selective outcome reporting. A detailed analysis of the summary of evidence for primary outcome is provided in Table 3 . After an extensive search of the literature, we included ten studies with data of 17,732 children. As compared with controls, those having documented infection with HCoV were at a higher risk of developing KD. No particular serotype of HCoV was found to be associated with this increased risk. The evidence, however, is of 'low certainty'. In a case-control study published in 2005, Esper et al. first demonstrated the association between HCoV infection and KD [16] . Chang et al. confirmed this association in 2014 [23] . However, further case-control studies failed to replicate this association [17, 20, 21] which was likely due to relatively small sample sizes in the two older studies. Of the ten studies included in the present review, eight used RT-PCR for detection of HCoV, and two used serological assays. Use of serological assays may have been the reason for low detection rates of HCoV in these studies, as sensitivity of serological assays is lower than RT-PCR. Furthermore, there is a significant variability among studies based upon the interval between diagnosis of KD and RT-PCR testing for HCoV infection. Additionally, only a few studies have documented presence of concomitant respiratory symptoms (due to HCoV infection) and occurrence of KD. In the present meta-analysis, we have analyzed the association of HCoV infections with KD. This has not been evaluated comprehensively to date. Recognition of association between HCoV with KD predates the KD or KDlike illnesses (in the form of multisystem inflammatory syndrome in children) seen in the ongoing SARS-CoV-2 pandemic by about a decade and a half. KD, KD-like illness (MIS-C/PIMS-TS) and severe COVID-19 infection induced vasculitis represent a similar disease spectrum characterized by a dysregulated immune response. It suggests that SARS-CoV-2 may just represent a 'new kid on the block' of various coronavirus infections associated with KD. In fact, KD has also been reported in association with the H1N1-pdm09 influenza infection that resulted in a pandemic a decade ago [26] . Besides, several other infectious illnesses have also been associated with KD [2] . Hence, there is a distinct possibility that there may be a surge in cases of KD or KD-like illnesses in future pandemics as well. Exact etiology of KD remains an enigma. Many infectious illnesses can trigger KD in a genetically susceptible host. Of the various microbial agents, respiratory viruses have come up as the most important triggers for KD [2] . Causality has not been proven for any of the associated infectious agents to date, although, a KD-specific RNA respiratory virus has been postulated to exist based largely on autopsy studies [27] . Epidemiological profile of KD also favors the theory of an infectious trigger as it is predominantly seen in children below 5 years, is associated with seasonal clustering of cases with occasional epidemics, and the clinical features (such as fever, rash, cervical lymphadenopathy) mimic an infectious disorder. It is plausible that HCoV infections may trigger KD illness in susceptible individuals. A number of genetic polymorphisms have been associated with an increased risk of developing KD in certain populations. Variability in HCoV-associated KD in different studies can therefore be easily explained by genetic differences among study populations [28] . It is possible that HCoV may be a risk factor for KD in populations with certain polymorphism(s) and not in others. The exact pathogenesis of KD following HCoV infection is poorly understood and multifactorial. Endothelial dysfunction or inflammation is the hallmark of both KD and KD-like conditions that follow HCoV and SARS-CoV2 infection. HCoV has spike like protein that binds to angiotensin converting enzyme 2 (ACE2) receptors on surface of the target cell. A systematic review and meta-analysis have documented a significant risk of KD with ACE2 polymorphism [29] . Additionally, ACE2 polymorphisms have also been associated with other systemic vasculitides. SARS-CoV-2 has been shown to modulate ACE2 expression resulting with elevated TNF-α production [30] . Thus, modulation of ACE2 expression as a result of coronavirus infection or genetic polymorphisms may be one of the unifying pathogenetic mechanisms between the KD/KD-like illnesses following coronavirus infection and KD not associated with coronavirus infection. A comprehensive literature search, robust analysis and grading of evidence are strengths of the present review. Inclusion of only retrospective studies into the pooled analysis is a limitation (albeit unavoidable) of our review as the small sample size and retrospective nature may have introduced bias to overall estimate of results. Another limitation is that only three authors were involved in search methodology, risk of bias assessment and data extraction. This overlapping role might have introduced some bias in the review process. Furthermore, all studies were hospital based and were conducted mostly in developed countries. Hence, it may not be prudent to extrapolate the findings of this meta-analysis to the community at large. A 'low certainty' of evidence suggests an increased risk of KD in children infected with HCoV. We need multicenter, prospective studies to support or refute this finding. The findings will be of great public health importance as KD/KD-like illnesses are closely associated with SARS-CoV-2 pandemic. There should be elucidation of actual link between Kawasaki disease, and human coronaviruses (both SARS and non-SARS) at molecular level so that targeted therapy can develop as a form of prophylaxis. • Many studies have analyzed the association between SARS-CoV-2 and Kawasaki disease (KD)/KD-like illnesses with conflicting results, however, systematic review(s) or meta-analyses that have studied the association between human coronavirus (HCoV) infection (non-SARS and non-MERS) and KD are lacking. Kawasaki disease: pathophysiology and insights from mouse models The epidemiology and pathogenesis of Kawasaki disease Update on Kawasaki disease: epidemiology, aetiology and pathogenesis Origin and evolution of pathogenic coronaviruses Multisystem inflammatory syndrome in children related to COVID-19: a New York city experience Kawasaki-like multisystem inflammatory syndrome in children during the COVID-19 pandemic Pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the United Kingdom and Ireland: what is new? Kawasaki and COVID-19 disease in children: a systematic review Characteristics of children With Kawasaki disease-like signs in COVID-19 pandemic: a systematic review Newcastle-Ottawa quality assessment scale: case control studies Review Manager (RevMan) [Computer program]. Version 5.3. The Nordic Cochrane Centre The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions Version5 Investigating and dealing with publication and other biases in meta-analysis The GRADE Working Group. GRADE handbook for grading quality of evidence and strength of recommendations Human coronavirus-NL63 infection is not associated with acute Kawasaki disease Association between a novel human coronavirus and Kawasaki disease Lack of association between New Haven coronavirus and Kawasaki disease Concurrent respiratory viruses and Kawasaki disease Kawasaki disease and human coronavirus Possible involvement of infection with human coronavirus 229E, but not NL63, in Kawasaki disease Kawasaki disease lacks association with human coronavirus NL63 and human bocavirus Blinded case-control study of the relationship between human coronavirus NL63 and Kawasaki syndrome Viral infections associated with Kawasaki disease Lack of association between infection with a novel human coronavirus (HCoV), HCoV-NH, and Kawasaki disease in Taiwan Human coronavirus NL63 is not detected in the respiratory tracts of children with acute Kawasaki disease Kawasaki disease and influenza -new lessons from old associations Ultrastructural, immunofluorescence, and RNA evidence support the hypothesis of a "new" virus associated with Kawasaki disease Immunogenetics of Kawasaki disease Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to Kawasaki disease: a meta-analysis Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry Meta-Analysis Patra, Das, Banday et al. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.